Cheaper biotherapeutic medicines are produced from biological sources rather than synthesised chemicals.
But the annual cost of the original drug is an average US$20,000, “a price that puts it out of reach of many women and healthcare systems in most countries,” the statement added.“With this WHO listing, and more products expected in the prequalification pipeline, prices should decrease even further,” the WHO said.
“Effective, affordable breast cancer treatment should be a right for all women, not the privilege of a few, ” he added.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: